Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report

Pembrolizumab is one of the approved treatments for many types of cancer including clear cell renal cell carcinoma (ccRCC). It has improved the prognosis of renal cell carcinoma, yet has many possible immune-related side effects. We discuss a rare case of rhabdomyolysis in an ccRCC patient treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Altermanini, Mohammad, Ali, Khaled, Alwassiti, Wisam, Almohtasib, Suliman, Omar, Nabil E., Zafar, Abdulaziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601742/
https://www.ncbi.nlm.nih.gov/pubmed/37900826
http://dx.doi.org/10.1159/000532100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601742/
https://www.ncbi.nlm.nih.gov/pubmed/37900826
http://dx.doi.org/10.1159/000532100

Ejemplares similares